NCT00622648 - Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin | Biotech Hunter

Enrollment

8,329

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Acute Illness

Interventions

DRUG

Enoxaparin

40 mg once daily for 6 to 14 days (10 ± 4 days)

DRUG

Placebo

Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)

Trial Locations (9)

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Shanghai

Sanofi-Aventis Administrative Office, Hong Kong

Sanofi-Aventis Administrative Office, Mumbai

Sanofi-Aventis Administrative Office, Kuala Lumpur

Sanofi-Aventis Administrative Office, Col. Coyoacan

Sanofi-Aventis Administrative Office, Makati City

Sanofi-Aventis Administrative Office, Seoul

Sanofi-Aventis Administrative Office, Mégrine